Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.